# HeartBeam, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/HeartBeam, Inc.). ## Overview HeartBeam, Inc. is a U.S. medical technology company developing a portable, cable-free ECG platform that captures cardiac signals in three dimensions and synthesizes a 12-lead ECG. Its system is designed for ambulatory use outside the hospital, with an initial focus on arrhythmia assessment and longer-term expansion into broader cardiac monitoring and heart-attack detection. ## Products & services • HeartBeam System: cable-free ambulatory 3D ECG device • 12L synthesis software for arrhythmia assessment • Patient application and physician portal workflow • Early access program for real-world product feedback • Clinical evidence generation and reference-site support - **Ambulatory ECG hardware** (45%) — Portable, credit-card-sized ECG recording devices used by patients outside a healthcare facility. - **ECG synthesis software** (25%) — Software that converts 3D cardiac signals into a synthesized 12-lead ECG for clinical interpretation. - **Clinical workflow software** (10%) — Patient and physician-facing applications that support data capture, review, and clinical use. - **Clinical validation and support** (20%) — Studies, reference-site development, and educational support used to drive adoption and reimbursement. - HeartBeam System cable-free ambulatory ECG device - 3D signal capture and synthesized 12-lead ECG software - Patient app and physician portal for remote workflow - Clinical studies and validation services supporting adoption - Early access program for pre-commercial user feedback ## Customers HeartBeam sells into clinical users rather than mass consumer channels, with early targets including concierge practices, preventative cardiology groups, cardiology departments in hospitals, and hospital-at-home programs. Healthcare insurers are also an important eventual customer because the company is trying to prove that its system can lower downstream costs and support coverage decisions. - **Concierge and preventative cardiology practices** (primary) — Buy the system to give patients access to a medical-grade ECG outside the clinic and to support premium care workflows. - **Hospital cardiology departments** (primary) — Use the device for ambulatory monitoring and diagnostic support where a standard 12-lead ECG is not practical. - **Hospital-at-home programs** (secondary) — Adopt the product for remote cardiac assessment in home-based care settings. - **Healthcare insurers and payers** (secondary) — May reimburse the system if HeartBeam proves clinical benefit and cost-effectiveness. - **Clinical trial sponsors and research sites** (emerging) — Use the platform in studies where portable, high-fidelity ECG data is needed. - Concierge physicians who want medical-grade ECG access at home - Cardiology practices seeking higher-resolution ambulatory monitoring - Hospital cardiology departments using the device for care pathways - Hospital-at-home programs needing remote cardiac assessment tools - Payers and insurers that may cover the system if cost savings are proven ## Geography HeartBeam’s initial commercial focus is the United States, where it has already run multicenter clinical studies and received FDA clearance for its system. The company says it will remain opportunistic internationally, and it already has a small patent footprint outside the U.S. in South Korea, Germany, France, the Netherlands, and the United Kingdom. - Initial commercial market is the United States - Clinical studies were run across five U.S. hospital sites - FDA clearance supports U.S. launch readiness - International expansion is opportunistic, not yet the main focus - Patent protection extends to several European and Asian markets ## Strategy HeartBeam’s strategy is to build clinical evidence first, then use that evidence to support commercial adoption and eventual payer reimbursement. Near term, it is focusing on a narrow launch with a small direct sales effort, reference sites, and early access feedback; longer term, it wants to expand into heart-attack detection, extended-wear monitoring, and partnering opportunities. - **Clinical validation and FDA-backed commercialization** (short-term) — Adoption depends on proving the system is clinically credible and usable in real-world settings. - **Reference-site and physician adoption** (short-term) — A small number of credible clinical sites can accelerate trust and reduce sales complexity. - **Payer reimbursement pathway** (medium-term) — Coverage would materially expand addressable demand and improve economics. - **Platform expansion and partnerships** (long-term) — Broader product functionality and licensing can extend the technology beyond the initial device launch. - Prove 12-lead equivalence and clinical utility through studies - Use reference sites and peer-reviewed data to drive adoption - Launch with a small direct sales network to conserve cash - Target non-reimbursed initial use cases before payer coverage - Pursue partnerships and licensing opportunities in ECG markets - Expand into heart-attack detection and extended-wear products ## Risks HeartBeam is still in an early commercialization stage, so its business depends on successful clinical validation, regulatory execution, and eventual market adoption. It also faces financing risk because it has required repeated equity funding, and competition is intense from much larger device and consumer wearable companies with established customer bases. - **Additional capital requirement** [high] — The company expects to need more funding to complete development and support growth, which could be dilutive or unavailable. - **Regulatory and clinical trial risk** [high] — Commercialization depends on FDA clearance and continued positive clinical evidence; setbacks would delay launch and adoption. - **Competitive pressure** [medium] — Apple, AliveCor, Google and other medtech firms have greater resources, brand recognition, and distribution. - **Reimbursement and market adoption risk** [high] — Initial targets may buy outside reimbursement, but broader scale likely requires payer coverage and proof of cost-effectiveness. - **Cybersecurity and data integrity** [medium] — The product handles sensitive health data, and breaches or data corruption could harm operations and reputation. - Needs additional capital to fund development and commercialization - Commercial launch depends on regulatory and clinical success - Competition includes larger medtech and consumer wearable firms - Adoption may be slow without reimbursement coverage - Cybersecurity or data loss could damage trust and operations - Small operating scale increases execution and hiring risk ## Accounting HeartBeam’s results are heavily influenced by non-cash stock-based compensation, milestone-based vesting judgments, and ongoing operating losses typical of an early-stage medtech company. Investors should also watch capital-raising accounting, since equity issuance has been a major source of cash, and future commercialization may introduce revenue recognition judgments once sales begin. - **Stock-based compensation** — Affects operating expense and net loss - **Milestone-based vesting estimates** — Can accelerate or defer equity compensation expense - **Future revenue recognition** — Will affect revenue timing and gross margin presentation - **Capital raise accounting** — Dilution and financing cash flow - Stock-based compensation is a major non-cash expense - Milestone-based vesting requires judgment on regulatory timing - Equity issuance affects dilution and financing cash flow - Commercial launch will introduce revenue recognition judgments - Impairment and capitalization judgments may matter as assets grow --- *Last updated: 2026-04-28T20:14:33.606647+00:00*